Study Of The Safety Of CE 224,545 And Methotrexate In Patients With Rheumatoid Arthritis

Completed · Phase 1

Conditions studied: Arthritis, Rheumatoid

In brief

CE 224,535 is being developed for the treatment of rheumatoid arthritis. The purpose of this study is to evaluate the safety and tolerability of CE 224,535 after 4 weeks of treatment in subjects with rheumatoid arthritis already receiving methotrexate

Key facts

Study ID

NCT00446784

Run by

Pfizer

People needed

20

Starts

2007-04-01

Expected to finish

2007-08-01

Last updated by the study team

2011-05-23

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults patients with rheumatoid arthritis
• Patients who have received stable weekly doses of oral methotrexate (5 to 25 mg/week administered as a single dose) for a minimum of 28 days (4 weeks/4 doses)

You may not qualify if…

• History of chronic infectious disease such as genitourinary, pulmonary or sinus infections.
• Any current or known malignancy or history of malignancy within the previous 5 years
• Pregnant or lactating women; women of child-bearing potential who are unwilling to unable to use an acceptable method of birth control during the study

Where it is running

• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Ocala, Florida, United States
• Pfizer Investigational Site — Ocala, Florida, United States
• Pfizer Investigational Site — Kalamazoo, Michigan, United States
• Pfizer Investigational Site — Ducansville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.